Introduction: Prostatic urethral lift (PUL) is a minimally invasive procedure for the treatment of lower urinary tract symptoms (LUTSs) secondary to benign prostatic hyperplasia (BPH). The PUL procedure involves the placement of implants that retract the obstructing prostate lobes. This procedure achieves quantifiable improvements in functional outcomes and quality of life (QoL), while preserving erectile and ejaculatory functions. Methods: Seventeen patients diagnosed with BPH who had undergone the UroLift® procedure between March 2011 and June 2015 were retrospectively evaluated. The parameters evaluated in the pre-operative, intra-operative and 1-year post-operative period were demographic data, and pre-operative, intra-operative and 1-year post-operative results were obtained from the International Prostate Symptom Score (IPSS), Uroflowmetry QoL index, International Index of Erectile Function (IIEF) and Male Sexual Health Questionnaire (MSHQ) for ejaculatory function (MSHQ-EjD). Results: The average improvements from baseline to 12 months after intervention were significant for the total IPSS 9.6. There was a 4.2-point increase in Qmax, a 0.9-point improvement in QoL and a 32% decrease in PVR. No statistically significant difference was found in the IIEF and MSHQ-EjD scores when the pre-operative and post-operative 3rd and 12th month scores were evaluated (p > 0.05). Conclusions: PUL offers rapid improvement in voiding and storage symptoms, QoL and flow rate that is durable to 12 months after intervention. PUL is a minimally invasive procedure that has the moderate effect in treating troublesome LUTS secondary to benign prostatic obstruction and preserving total sexual function.

Keywords:
Prostatic urethral lift, Benign prostatic hyperplasia, Minimally invasive surgery
1.
Roehrborn CG: Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 2008;10:14-25.
2.
Nordling J: Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95:1006-1012.
3.
Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, et al: Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011;108:82-88.
4.
Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC: Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol 2003;44:539-545.
5.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140.
6.
Rassweiler J, Teber D, Kuntz R, Hofmann R: Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol 2006;50:969-980; discussion 980.
7.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al: Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-1803.
8.
Barkin J, Giddens J, Incze P, Casey R, Richardson S, Gange S: UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol 2012;19:6217-6222.
9.
McNicholas TA, Woo HH, Chin PT, Bolton D, Fernández Arjona M, Sievert KD, et al: Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 2013;64:292-299.
10.
Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, et al: Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012;79:5-11.
11.
National Institute for Health and Care Excellence (NICE): Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, 2014.
12.
National Institute for Health and Care Excellence (NICE): Interventional procedure overview of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia: overview, 2014.
13.
Perera M, Roberts MJ, Doi SA, Bolton D: Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 2015;67:704-713.
14.
Shore N, Freedman S, Gange S, Moseley W, Heron S, Tutrone R, et al: Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol 2014;21:7094-7101.
15.
McVary KT, Gange SN, Shore ND, Bolton DM, Cowan BE, Brown BT, et al: Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med 2014;11:279-287.
16.
Garrido Abad P, Coloma Del Peso A, Sinues Ojas B, Fernández Arjona M: [Urolift®, a new minimally invasive treatment for patients with low urinary tract symptoms secondary to BPH. Preliminary results]. Arch Esp Urol 2013;66:584-591.
17.
Delongchamps NB, Conquy S, Defontaines J, Zerbib M, Peyromaure M: [Intra-prostatic UroLift (®) implants for benign prostatic hyperplasia: preliminary results of the four first cases performed in France]. Prog Urol 2012;22:590-597.
18.
Akın Y, Bozkurt A, Keles MO, Gulmez H, Sahin M, Nuhoglu B: Benign Prostat Hiperplazisi'nin Yeni Minimal İnvaziv Tedavi Secenegi: Prostat İçerisine UroLift® Uygulaması, Erken Dönem Sonuçları ile Turkiye'den ilk Vaka Serisi. JAREM 2013;3:74-78.
19.
Broggi E, May A, Giretti G, Tabchouri N, Lorphelin H, Brichart N, et al: Long-term outcomes of 80-watt KTP and 120-watt HPS GreenLight photoselective vaporization of the prostate. Urol Int 2014;93:229-236.
20.
Bulut S, Ozden C, Aktas BK, Deren T, Tagci S, Gokkaya CS, et al: Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia. Urol Int 2015;94:181-186.
21.
Lukacs B, Loeffler J, Bruyère F, Blanchet P, Gelet A, Coloby P, et al: Photo selective vaporization of the prostate with Green Light 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol 2012;61:1165-1173.
22.
Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al: The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the LIFT study. J Urol 2013;190:2161-2167.
23.
Cantwell AL, Bogache WK, Richardson SF, et al: Multicentre prospective crossover study of the ‘prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 2014;113:615-622.
24.
Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, et al: Durability of the prostatic urethral lift: 2-year results of the LIFT study. Urol Pract 2015;2:26-32.
25.
Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, et al: Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012;9:CD004135.
26.
Frieben RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE, Wang R: The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. Asian J Androl 2010;12:500-508.
27.
Hoffman RM, MacDonald R, Wilt TJ: Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev 2004;1:CD001987.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.